Literature DB >> 21250864

Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells.

Christin Flechsig1, Yasemin Suezer, Markus Kapp, Sen Mui Tan, Jürgen Löffler, Gerd Sutter, Hermann Einsele, Goetz Ulrich Grigoleit.   

Abstract

BACKGROUND AIMS: Modified vaccinia Ankara (MVA) is a promising vaccine vector for infectious diseases and malignancies. It is fundamental to ascertain its tropism in human leukocyte populations and immunostimulatory mechanisms for application in immunotherapy.
METHODS: Human peripheral blood mononuclear cells (PBMC) and leukocyte subpopulations [monocyte-derived dendritic cells (DC), monocytes and B cells] were infected with MVA in order to evaluate their infection rate, changes in surface markers, cytokine expression and apoptosis.
RESULTS: Monocytes, DC and B cells were most susceptible to MVA infection, followed by natural killer (NK) cells. Monocytes were activated strongly, with upregulation of co-stimulatory molecules, major histocompatibility complex (MHC) molecules and chemokine (C-C motif) receptor (CCR7), while immature DC showed partial activation and B cells were inhibited. Furthermore, expression of chemokine (C-X-C motif) ligand (CXCL10), tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-12p70 was enhanced but IL-1β and IL-10 were stable or even downregulated. MVA induced a high apoptosis rate of antigen-presenting cells (APC). Nevertheless, incubation of MVA-infected leukocytes with uninfected immature DC (iDC) led to complete maturation of the DC. Subsequently, the matured DC were able to stimulate cytomegalovirus (CMV)-immediate early protein (IE1)-specific T cells.
CONCLUSIONS: MVA induces a T-helper (Th)-1-polarizing cytokine expression in APC. Furthermore, incubation of MVA-infected leukocytes with uninfected iDC leads to complete maturation of the DC and may be the basis for cross-presentation of MVA-encoded antigens. Thus this approach seems to be an ideal model for further studies with MVA-encoded viral antigens regarding immunotherapy and vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21250864     DOI: 10.3109/14653249.2010.549123

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  11 in total

Review 1.  Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines.

Authors:  Houda Boukhebza; Nadine Bellon; Jean Marc Limacher; Geneviève Inchauspé
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

Review 2.  I'm Infected, Eat Me! Innate Immunity Mediated by Live, Infected Cells Signaling To Be Phagocytosed.

Authors:  Tim Birkle; G C Brown
Journal:  Infect Immun       Date:  2021-04-16       Impact factor: 3.441

3.  Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation.

Authors:  E Guzman; C Cubillos-Zapata; M G Cottingham; S C Gilbert; H Prentice; B Charleston; J C Hope
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

4.  Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara.

Authors:  Philip J R Price; Bruno Luckow; Lino E Torres-Domínguez; Christine Brandmüller; Julia Zorn; Carsten J Kirschning; Gerd Sutter; Michael H Lehmann
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

5.  Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.

Authors:  Arwen F Altenburg; Carolien E van de Sandt; Bobby W S Li; Ronan J MacLoughlin; Ron A M Fouchier; Geert van Amerongen; Asisa Volz; Rudi W Hendriks; Rik L de Swart; Gerd Sutter; Guus F Rimmelzwaan; Rory D de Vries
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

6.  Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine.

Authors:  Pierre Rosenbaum; Nicolas Tchitchek; Candie Joly; Lev Stimmer; Hakim Hocini; Nathalie Dereuddre-Bosquet; Anne-Sophie Beignon; Catherine Chapon; Yves Levy; Roger Le Grand; Frédéric Martinon
Journal:  Front Immunol       Date:  2018-04-25       Impact factor: 7.561

7.  Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures.

Authors:  Jessamine E Hazlewood; Troy Dumenil; Thuy T Le; Andrii Slonchak; Stephen H Kazakoff; Ann-Marie Patch; Lesley-Ann Gray; Paul M Howley; Liang Liu; John D Hayball; Kexin Yan; Daniel J Rawle; Natalie A Prow; Andreas Suhrbier
Journal:  PLoS Pathog       Date:  2021-01-13       Impact factor: 6.823

8.  CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

Authors:  Hannah R Sharpe; Nicholas M Provine; Georgina S Bowyer; Pedro Moreira Folegatti; Sandra Belij-Rammerstorfer; Amy Flaxman; Rebecca Makinson; Adrian Vs Hill; Katie J Ewer; Andrew J Pollard; Paul Klenerman; Sarah Gilbert; Teresa Lambe
Journal:  JCI Insight       Date:  2022-03-22

9.  Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.

Authors:  Beatriz Perdiguero; Carmen Elena Gómez; Jose Luis Nájera; Carlos Oscar S Sorzano; Julie Delaloye; Rubén González-Sanz; Victoria Jiménez; Thierry Roger; Thierry Calandra; Giuseppe Pantaleo; Mariano Esteban
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.

Authors:  José I Quetglas; Liza B John; Michael H Kershaw; Luis Alvarez-Vallina; Ignacio Melero; Phillip K Darcy; Cristian Smerdou
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.